Penumbra Inc reported first quarter ended March 31, 2026 results: revenue $374.8 million, net income $32.6 million.
“Penumbra, Inc. Reports First Quarter 2026 Financial Results ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. • Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. • Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. • Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. • Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. • Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pendin”
Material Agreements
Penumbra Inc entered into Agreement and Plan of Merger with Boston Scientific Corporation (effective 2026-01-14).
“On January 14, 2026, Penumbra, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent.”
Don Kassing retired as Director at Penumbra Inc.
“On February 14, 2025, Don Kassing, a member of the Board of Directors (the “Board”) of Penumbra, Inc. (the “Company”), notified the Company that he will retire from the Board effective April 1, 2025.”
Earnings Releases
Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.
“Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.